Skin involvement represents the most frequent and often earliest manifestation of both acute and chronic GvHD, with significant diagnostic and therapeutic implications. In this episode, Dr. Marawan and Dr. Yousef provide a comprehensive, multidisciplinary review of clinical presentation, differential diagnosis, histopathologic correlation, NIH grading criteria, and the functional and quality-of-life impact of cutaneous GvHD. The discussion also addresses challenges in distinguishing chronic skin GvHD from autoimmune mimickers and highlights the importance of early recognition and coordinated care to optimize patient outcomes.

Eosinophilic inflammation has multiple drivers^1,2

Screening for individuals with first-degree relatives with T1D, particularly those with high-risk and Regular monitoring of autoantibodies and glucose tolerance can facilitate earlier diagnosis and treatment initiation.